Joanna E Khatib1, Yixue Shao2, Lizheng Shi2, Vivian A Fonseca1. 1. Tulane University Health Sciences Center, New Orleans, Louisiana, USA. 2. Department of Health Policy and Management, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana, USA.
Abstract
OBJECTIVE: We conducted a meta-analysis to compare major adverse cardiovascular events (MACEs) in recent diabetes type 2 drugs cardiovascular outcome trials (CVOTs) in the subgroups that used insulin at baseline to the subgroups that did not. METHODS: English publications from 2010 to 2019 were searched in PubMed and Google Scholar. We searched published clinical trials for CVOTs with new drugs for type 2 diabetes and found 12 publications, of which 8 provided outcomes according to insulin use. We compared the event rate of the primary outcome in the group taking insulin with the one not taking insulin. Data were extracted by 2 investigators independently, including CVOT drug, publication year, sample size, duration of diabetes, mean glycated hemoglobin A1c, mean age, and number of patients in each treatment group. We included 8 trials in the analysis: DECLARE, EMPA-REG, EXSCEL, HARMONY, LEADER, SUSTAIN-6, EXAMINE, and SAVOR-TIMI. The pooled relative risk was 1.52 (95% CI, 1.43 ~ 1.62) when comparing the treatment group with insulin at baseline with the treatment group of patients without insulin use. RESULTS: In recent CVOTs, patients on insulin regimen along with the new antidiabetic drug had a higher risk ratio of cardiovascular events than patients who used the new antidiabetic drug alone. Published by Oxford University Press on behalf of the Endocrine Society 2020.
OBJECTIVE: We conducted a meta-analysis to compare major adverse cardiovascular events (MACEs) in recent diabetes type 2 drugs cardiovascular outcome trials (CVOTs) in the subgroups that used insulin at baseline to the subgroups that did not. METHODS: English publications from 2010 to 2019 were searched in PubMed and Google Scholar. We searched published clinical trials for CVOTs with new drugs for type 2 diabetes and found 12 publications, of which 8 provided outcomes according to insulin use. We compared the event rate of the primary outcome in the group taking insulin with the one not taking insulin. Data were extracted by 2 investigators independently, including CVOT drug, publication year, sample size, duration of diabetes, mean glycated hemoglobin A1c, mean age, and number of patients in each treatment group. We included 8 trials in the analysis: DECLARE, EMPA-REG, EXSCEL, HARMONY, LEADER, SUSTAIN-6, EXAMINE, and SAVOR-TIMI. The pooled relative risk was 1.52 (95% CI, 1.43 ~ 1.62) when comparing the treatment group with insulin at baseline with the treatment group of patients without insulin use. RESULTS: In recent CVOTs, patients on insulin regimen along with the new antidiabetic drug had a higher risk ratio of cardiovascular events than patients who used the new antidiabetic drug alone. Published by Oxford University Press on behalf of the Endocrine Society 2020.
Entities:
Keywords:
cardiovascular outcomes; trials; type 2 diabetes
Authors: Darren K McGuire; Nikolaus Marx; Odd Erik Johansen; Silvio E Inzucchi; Julio Rosenstock; Jyothis T George Journal: Diabetes Obes Metab Date: 2019-03-12 Impact factor: 6.577
Authors: Bernard Zinman; Christoph Wanner; John M Lachin; David Fitchett; Erich Bluhmki; Stefan Hantel; Michaela Mattheus; Theresa Devins; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Silvio E Inzucchi Journal: N Engl J Med Date: 2015-09-17 Impact factor: 91.245
Authors: Marc A Pfeffer; Brian Claggett; Rafael Diaz; Kenneth Dickstein; Hertzel C Gerstein; Lars V Køber; Francesca C Lawson; Lin Ping; Xiaodan Wei; Eldrin F Lewis; Aldo P Maggioni; John J V McMurray; Jeffrey L Probstfield; Matthew C Riddle; Scott D Solomon; Jean-Claude Tardif Journal: N Engl J Med Date: 2015-12-03 Impact factor: 91.245
Authors: Adrian F Hernandez; Jennifer B Green; Salim Janmohamed; Ralph B D'Agostino; Christopher B Granger; Nigel P Jones; Lawrence A Leiter; Anne E Rosenberg; Kristina N Sigmon; Matthew C Somerville; Karl M Thorpe; John J V McMurray; Stefano Del Prato Journal: Lancet Date: 2018-10-02 Impact factor: 79.321
Authors: David Moher; Larissa Shamseer; Mike Clarke; Davina Ghersi; Alessandro Liberati; Mark Petticrew; Paul Shekelle; Lesley A Stewart Journal: Syst Rev Date: 2015-01-01
Authors: Kai McKeever Bullard; Catherine C Cowie; Sarah E Lessem; Sharon H Saydah; Andy Menke; Linda S Geiss; Trevor J Orchard; Deborah B Rolka; Giuseppina Imperatore Journal: MMWR Morb Mortal Wkly Rep Date: 2018-03-30 Impact factor: 17.586
Authors: Steven P Marso; Gilbert H Daniels; Kirstine Brown-Frandsen; Peter Kristensen; Johannes F E Mann; Michael A Nauck; Steven E Nissen; Stuart Pocock; Neil R Poulter; Lasse S Ravn; William M Steinberg; Mette Stockner; Bernard Zinman; Richard M Bergenstal; John B Buse Journal: N Engl J Med Date: 2016-06-13 Impact factor: 176.079
Authors: Priyanka Kushwaha; Seva G Khambadkone; Mengni Li; Ethan J Goodman; Nandini Aravindan; Ryan C Riddle; Kellie L K Tamashiro Journal: Calcif Tissue Int Date: 2021-01-02 Impact factor: 4.333